Vestmark Advisory Solutions Inc. Has $15.49 Million Stock Position in CRISPR Therapeutics AG $CRSP

Vestmark Advisory Solutions Inc. reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 50.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 238,962 shares of the company’s stock after selling 246,013 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in CRISPR Therapeutics were worth $15,487,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC raised its stake in shares of CRISPR Therapeutics by 6.1% in the third quarter. Axxcess Wealth Management LLC now owns 12,258 shares of the company’s stock valued at $794,000 after acquiring an additional 708 shares during the last quarter. Merit Financial Group LLC bought a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $678,000. Vanguard Group Inc. increased its holdings in CRISPR Therapeutics by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock valued at $153,253,000 after purchasing an additional 66,556 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in CRISPR Therapeutics by 98.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock valued at $38,459,000 after purchasing an additional 294,222 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in CRISPR Therapeutics by 15.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,631 shares of the company’s stock valued at $430,000 after purchasing an additional 876 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Pipeline and earnings reaction — MarketBeat notes investors cheered Q4 results for pipeline progress and CASGEVY adoption (cash runway ~ $1.9B, CTX611 upside). That optimism helped the stock rebound after earnings even though reported revenue was small due to revenue-sharing with Vertex. CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
• Positive Sentiment: Bull case on long-term upside — Seeking Alpha highlights a “Buy” thesis driven by CASGEVY launch economics and CTX611 potential (modeled high peak sales), arguing significant upside exists despite high risk. Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
• Neutral Sentiment: Short-interest data ambiguous — reported short interest entries show zero shares/NaN changes and a 0.0 days ratio, which appears to be a reporting artifact rather than meaningful positioning information. No clear short-squeeze or build-up signal.
• Neutral Sentiment: Reassessment pieces — coverage (Yahoo) asks whether the recent rebound warrants a rethink, reflecting mixed analyst views and technical levels to watch; useful for investors weighing timing. Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Share Price Rebound?
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni and General Counsel James Kasinger sold shares on Feb 19 (CEO ~6,967 shares; GC ~2,112 shares), modestly reducing their positions. Insider sales can signal near-term caution to some investors. CEO Filing GC Filing
• Negative Sentiment: Near-term fundamentals and skepticism — Q4 showed a big EPS miss and revenue limited by a revenue-share with Vertex; some analysts (e.g., Morgan Stanley cited in coverage) remain cautious with low price targets. Pessimistic takes (Fool) question the long-term payoff versus risk. Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 6,967 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $366,324.86. Following the completion of the sale, the chief executive officer owned 226,106 shares in the company, valued at approximately $11,888,653.48. This represents a 2.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 2,112 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the transaction, the general counsel owned 85,115 shares in the company, valued at approximately $4,475,346.70. This trade represents a 2.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 99,079 shares of company stock valued at $5,643,674 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CRSP shares. Wedbush cut their price target on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Citizens Jmp reduced their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research report on Friday, January 30th. Evercore reissued an “outperform” rating and issued a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Finally, Morgan Stanley restated an “underweight” rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Trading Down 2.2%

Shares of NASDAQ CRSP opened at $53.46 on Friday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The firm’s 50-day moving average is $53.84 and its 200-day moving average is $57.24. The firm has a market capitalization of $5.13 billion, a PE ratio of -8.20 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $4.72 million. During the same period last year, the firm earned ($1.01) earnings per share. The company’s quarterly revenue was down 97.8% on a year-over-year basis. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.